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Edited by Richard MaraisAbstract Thymidine phosphorylase (TP) is involved both in
pyrimidine nucleoside metabolism and in angiogenesis. TP also
conferred the resistance to hypoxia-induced apoptosis of the
cancer cells. In U937 cells, DNA damage-inducing agents sig-
niﬁcantly enhanced the expression of TP. Cell lines stably
transfected with TP cDNA were more resistant to the DNA
damage-inducing agents than the mock-transfected cells and
showed augmented activity of Akt. The cytoprotective function
of TP against DNA damage was independent of its enzymatic
activity. The resistance to apoptosis was partially abrogated
by treatment with the phosphatidyl inositol 3-kinase (PI3K)
inhibitors, suggesting that the cytoprotective function of TP is
mediated, at least in part, by regulation of the PI3K/Akt path-
way. These ﬁndings indicate that TP expression in increased by
various stress including DNA damage and that TP molecules
confer resistance to DNA damage-induced apoptosis in cancer
cells.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Thymidine phosphorylase (TP) is an enzyme that has un-
ique properties. TP catalyzes the reversible conversion of thy-
midine to thymine and 2-deoxy-D-ribose-1-phosphate, TP is
also involved in endothelial cell chemotaxis in vitro and angi-
ogenesis in vivo [1]. TP expression in various kinds of tumors
is higher than in the adjacent non-neoplastic tissues, and
numerous studies have consistently reported that the level
of TP expression in cancer cells is closely associated with
malignancy and/or angiogenesis [2–5]. However, in colorectal
carcinomas, TP expression is an independent indicator of
unfavorable prognosis irrespective of angiogenetic activity
[6]. These data suggest that TP may contribute to the malig-*Corresponding author. Fax: +81 99 265 9687.
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doi:10.1016/j.febslet.2006.01.047nant character of cancer cells through mechanisms other than
its angiogenic activity.
We previously reported that TP might enhance tumor pro-
gression by conferring resistance to hypoxia-induced apoptosis
of cancer cells. We showed that 2-deoxy-D-ribose, a dephos-
phorylated product of 2-deoxy-D-ribose-1-phosphate, partially
inhibited this apoptosis [7], suggesting that a second function
of TP might be the inhibition of apoptosis induced by various
stresses in tumor cells. We have also demonstrated that TP-
transfected cell lines are more resistant to various apoptosis-
inducing stimuli such as Fas and cisplatin [8,9]. However, the
mechanisms by which TP expression is enhanced in response
to stressful conditions and by which it modulates apoptosis
are largely unclear.
Akt/PKB (protein kinase B) is a serine/threonine protein ki-
nase that regulates diverse cellular processes but may play a
critical role in cell survival following exposure to DNA-dam-
age inducing agents. Akt is activated following binding to
PI3K. Recently, Akt has been implicated in the inhibition of
apoptosis in a variety of cell types in vitro including cancer
cells. The anti-apoptotic function of Akt is reported to be med-
iated by its ability to phosphorylate and inactivate apoptotic
regulatory molecules including BAD, caspase-9, IKK-a and
the forkhead transcription factor FKHRL [10,11].
In this study, we investigated the role of TP in apoptosis in-
duced by DNA damage as well as the biological mechanisms
by which TP functions as an anti-apoptotic agent. We found
that both the transcriptional activity, and the protein expres-
sion, of TP were enhanced by DNA damage-inducing agents.
Moreover, we also found that TP confers cytoprotection
against DNA damaging agents on tumor cells, and that TP-in-
duced anti-apoptotic eﬀects are at least partly mediated
through regulation of the PI3K/Akt survival pathways.2. Materials and methods
2.1. Reagents and antibodies
VP-16, cisplatin, doxorubicin, vincristine, staurosporine, vinblastine,
paclitaxel, thymidine, and thymine were purchased from Sigma Chem-
ical (St. Louis, MO). Human recombinant IFN-c was from PeproTech
(London, UK). The anti-mouse monoclonal anti-Akt and phospho-
Akt from Cell Signaling (Beverly, MA) and anti-p53 (Ab-6) from
Oncogene (Boston, MA).blished by Elsevier B.V. All rights reserved.
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ceutical Co. Ltd. (Saitama, Japan), and described previously [12].
The PI3K inhibitors Wortmannin and LY294002 were obtained from
Sigma and Calbiochem, respectively.
2.2. Plasmids
The TP promoter fragment, fused upstream of the luciferase gene
(pTP-Luc1), was a generous gift from Dr. M. Ono (Kyushu Univer-
sity), as described previously [13]. Full-length TP cDNA was kindly
provided by Dr. K. Miyazono (Tokyo University) and Dr. C-H. Hel-
din (Ludwig Institute for Cancer Research, Uppsala, Sweden). A
KpnI–EcoRI fragment from pPL8 that encompassed the TP coding re-
gion was cloned between the KpnI and EcoRI restriction sites of
pT7T318U (Pharmacia, Uppsala, Sweden). A XbaI–EcoRI fragment
from pT7T318U was then cloned between the NheI and EcoRI restric-
tion sites of expression vector pBK-RSV (Stratagene, La Jolla, CA) to
make the expression vector encoding TP cDNA (RSV/TP). As a mu-
tant, TP (L148R) which has no TP activity was prepared and ligated
into same vector (RSV/L148R). Wild-type (pC53-SN3) and mutant-
type (pC53-CxAN) p53 plasmids were described previously [14].
2.3. Cell culture and establishment of TP-overexpressing cell lines
The cell lines U937 (human myeloid leukemia), KB (human epider-
moid carcinoma), Jurkat (human T-cell leukemia), HCT-15 (human
colorectal cancer) and Saos-2 (human osteosarcoma) were obtained
from the American Type Culture Collection (Rockville, MD). KB cells
were maintained in (MEM). U937, Jurkat and HCT-15 were cultured
in RPMI 1640, whereas Saos-2 was maintained in Dulbecco’s MEM
(DMEM).
The expression vector encoding TP cDNA (RSV/TP) or the vector
alone (RSV) was transfected into KB cells by electroporation. As a
mutant, L148R which has no TP activity was also transfected into
KB cells. After selection with Geneticin, the expression of TP in each
clone was determined by immunoblotting with anti-TP monoclonal
antibody. TP-positive clones transfected with RSV/TP (KB/TP cells),
RSV/L148R (KB/TP-mt L148R) and one clone transfected with RSV
(KB/CV cells) were further analyzed [15].
2.4. Transient transfection and luciferase assay
All the transfection procedures were performed using Lipofect-
AMINE reagent (Invitrogen) according to the manufacturer’s protocol.
Brieﬂy, U937 cells were plated at a density of 4 · 106/well in 6-well
plates. Cells were co-transfected with 5 lg of the TP-promoter-lucifer-
ase plasmid DNA and 100 ng of pRL-CMV vector as an internal con-
trol. Following induction for 18–24 h cells were treated with various
stimuli including hypoxia, hyperosmolarity (150 mM NaCl), serum
starvation, acidosis (pH 6.5) and DNA damage-inducing agents
(described below) and were incubated for a further 18–24 h. Cells were
harvested and their luciferase activity was analyzed using a Dual-Lucif-
erase Assay according to the manufacturer’s instructions (Promega,
Madison, WI). Treatment of U937 cells with 50 U/ml IFN-c was used
as a positive control.
Saos-2 cells were transfected with 200 ng of the p53-expressing plas-
mid and 1.8 lg of the TP-promoter luciferase plasmid DNA. After
18 h incubation the cells were incubated with or without 10 lM VP-
16 or UV (40 J/m2) exposure. The cells were harvested 24 h later and
luciferase activities were determined. Each procedure was performed
in triplicate and the results are displayed as the means ± S.D.
2.5. Induction of DNA damage
Cells were plated at a density of 1 · 106 cells/well 24 h before treat-
ment. VP-16, doxorubicin, and cisplatin, at the indicated doses, were
added and incubated for another 36 h. For UV irradiation, culture
medium was removed for the brief irradiation period and then imme-
diately replaced. Hypoxia was induced with a Gas Pak Pouch Anaer-
obic System (Becton Dickinson and Company, Cockeysville, MD).
2.6. Determination of cell viability by the 3-(4,5-dimethylthazol-2-yl)-
2,5-diphenyltetrazolium bromide assay
The 3-(4,5-dimethylthazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay was used to screen the relative sensitivity of cells to
DNA damage-inducing agents. 1 · 104 cells in 200 ll of culture med-
ium were inoculated into each well of a 96-well plate with various con-centrations of DNA damage-inducing agents with or without 200 lM
of TPI. The plates were incubated for 3 days and the MTT assay was
performed as previously described [16]. Relative resistance was calcu-
lated by dividing the IC50 of the TP-overexpressing cells by that of
the mock-transfected cells.
2.7. Measurement of apoptotic cells and cell cycle stage
Apoptotic cells were quantiﬁed by ﬂow cytometry. Cells treated with
DNA damage stimuli for 36 h were harvested and washed once with
PBS. For ﬂow cytometry, 1 · 104 cells were suspended in 100 ll PBS
and mixed with 100 ll of COULTER DNA-Prep LPR (COULTER,
Miami, FA) and then 2 ml of COULTER DNA-Prep Stain was added.
The mixtures were incubated for 15 min at room temperature. The cell
cycle stage of the cells was determined as described previously [17]
using the EPICS ALTRA (Beckman Coulter, Tokyo, Japan). Apopto-
tic cells were estimated by determination of the proportion of the cells
present that were in the sub-G1 stage of the cell cycle.
2.8. TP activities
For radiometric assay, enzymatic activities were determined by mea-
suring the conversion of [14C] thymidine to [14C] thymine as described
previously [18] with slight modiﬁcation. KB/TP and KB/CV cells were
seeded at 1 · 106 cells/well in 12 well plates and [14C] thymidine was
then added in the each culture media and incubated at 37 C for 1 h.
Aliquots of media were spotted on PEI-cellulose chromatography
plates. Aliquots of 10 mM thymidine and 1 mM thymine were spotted
as standards. The plates were developed in a solvent system of chloro-
form–methanol–acetic acid 17:3:1. The nucleoside and base were iden-
tiﬁed under UV light, scraped out and analyzed for radioactivity. The
ratios of radioactivity of [14C] thymine to total radioactivity were
determined.
2.9. Immunoblotting
Exponentially growing cells were seeded at 106 per 60 cm2 dish and
incubated for 36 h. Cells were harvested and resuspended in lysis buﬀer
[50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% NP-40,
1 mM sodium orthovanadate, 1 mM NaF, 10 lg/ml aprotinin, 10 lg/
ml leupeptin, 1 mM PMSF]. The cytosol fractions were subjected to
sodium dodecyl sulfate–polyacrylamide electrophoresis (SDS–PAGE)
and blotted onto PVDF membrane. The membrane was then incu-
bated with appropriate primary antibody overnight at 4 C and then
with a peroxidase-linked secondary antibody for 1 h at room temper-
ature. The membrane was developed by chemiluminescence according
to the manufacturer’s protocol (Amersham, Buckinghamshire, UK).
2.10. Statistical analysis
Quantitative data were expressed as the means ± S.D. Statistical
comparisons were performed using the Student’s t test. Diﬀerences
were regarded as signiﬁcant when probability values were <0.05.3. Results
3.1. TP promoter activity is enhanced by various stresses
including DNA damage-inducing agents
To determine if cellular stresses could modulate expression of
the TP gene we assayed the eﬀect of various cellular stresses on
TP promoter activity using a luciferase reporter assay. The TP
promoter, fused upstream of the luciferase gene (pTP-Luc1),
was transfected into U937 cells. IFN-c, which is known to en-
hance TP transcriptional activity [19] induced a 2.5-fold increase
of the luciferase activity over the basal level. Exposure of the cell
to hypoxic stress, hyperosmotic shock and simultaneous serum
starvation and acidosis, also signiﬁcantly enhanced the lucifer-
ase activity by 2.5, 2.7, and 3.2-fold, respectively (Fig. 1A). TP
promoter activity was also enhanced 3.2-fold following treat-
ment with thymidine but not with thymine.
We next investigated the eﬀect on TP promoter activity of
DNAdamage induced byUV, cisplatin, VP-16 and doxorubicin.
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Fig. 1. Speciﬁc cellular stresses activate the transcriptional activity of the TP gene promoter. The pTP-Luc1 was co-transfected with the pRL-CMV
vector into U937 cells. Following 18–24 h of induction, the cells were exposed to hypoxia, hyperosmolarity (150 mM NaCl), serum starvation and
acidosis (pH 6.5), thymidine (100 lM) or thymine (5 lM) in A, or to the DNA damage-inducing agents UV, cisplatin, VP-16 (5 lM), doxorubicin
(0.4 lM), vinblastine (10 ng/ml), vincristine (1 ng/ml), paclitaxel (10 lM), or staurosporine (50 ng/ml) in B as indicated. Following incubation for a
further 18–24 h, cells were harvested and luciferase activity was analyzed. Treatment of U937 cells with 50 U/ml IFN-c was used as a positive control.
Each column and bar represents the means ± S.D. of three independent experiments. *p < 0.01. (C) Protein expression levels of TP following
treatment over 48 h with UV (40 J/m2); cisplatin (20 lM) or vincristine (1 ng/ml) as indicated were assessed by immunoblotting. Cells were harvested
and resuspended in lysis buﬀer (50 mM Tris–HCl, pH 7.4, 150 mMNaCl, 1 mM EDTA, 1% NP-40, 1 mM sodium orthovanadate, 1 mMNaF, 10 lg/
ml aprotinin, 10 lg/ml leupeptin, 1 mM PMSF). Cytosolic fractions (50 lg of protein) were separated by SDS–9.4% PAGE. TP levels were
determined using an anti-TP monoclonal antibody.
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augmented by all of these DNA damage-inducing stimuli.
UV and cisplatin dose dependently upregulated the TP
promoter activity. UV had the strongest eﬀect, at a dose of
50 J/m2, the luciferase activity was 4.7-fold higher than the
basal level. 5 lM VP-16 and 4 lM doxorubicin also induced
an approximate 3-fold-increase in luciferase activity. By con-
trast, the luciferase activity was not elevated by 50 ng/ml
staurosporine, 1 ng/ml vincristine, 10 ng/ml vinblastine nor
10 lM paclitaxel. These data suggest that TP promoter activity
is speciﬁcally enhanced by DNA damage-inducing agents.
3.2. TP is increased at the protein level in response to DNA
damage-inducing agents
We next examined whether the cellular stresses that en-
hanced TP-promoter activity could also enhance TP expres-
sion at the protein level in U937 cells. Hypoxic stress was
used as a positive control since this stress has been reported
to augment TP protein levels. The cells were harvested, lysed
in the lysis buﬀer [50 mM Tris–HCl (pH 7.4), 150 mM NaCl,
1 mM EDTA, 1% NP-40, 1 mM sodium orthovanadate,1 mM NaF, 10 lg/ml aprotinin, 10 lg/ml leupeptin, 1 mM
PMSF] and applied cytosol fraction on the gel. Immunoblot-
ting analysis of TP showed a time-dependent increase of TP
protein expression following exposure to UV, cisplatin and hy-
poxia (Fig. 1C). Vincristine and staurosporin (data not shown)
induced little TP expression.
3.3. TP promoter activity is enhanced by p53
DNA damage-inducing stimuli cause cell cycle arrest or
apoptosis, and one of the major executors in these pathways
is p53. P53 levels are increased by these stimuli. Therefore,
we investigated whether the TP-promoter activity might be
inﬂuenced by p53. P53-null Saos-2 cells were co-transfected
with pTP-Luc1 and pC53 [pC53-SN3 (wild-type, wt) or
pC53-CxAN (point mutation, mt)], and analyzed in the TP-
promoter luciferase assay. Transfection of wt-p53 alone
induced a dramatic, 3.2-fold enhancement of TP-promoter
activity compared to background levels (denoted as 1.0),
whereas little change in TP-promoter activity was observed in
mt-p53-transfected cells (Fig. 2). Treatment with 10 lM VP-
16 or 40 J/m2 UV further enhanced the TP promoter activity
(-) VP-16 UV (-) VP-16 UV (-) VP-16 UV
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Fig. 2. The eﬀects of p53 on TP promoter activity. P53-null Saos-2
cells were co-transfected with a wild-type (WT) or mutant (mt) p53-
expressing plasmid and luciferase plasmid DNA using Lipofectamine.
After 18 h, the cells were gently washed with DMEM, and subse-
quently incubated with serum-containing medium in the absence () or
presence of 10 lMVP-16 or 40 J/m2 UV. The cells were harvested 24 h
later and luciferase activities were determined. All the assays were
carried out in triplicate and the results are displayed as the
means ± S.D.
Table 1
Eﬀects of TP on the cytotoxicity of DNA-damaging agents
IC50 (lM) Fold resistance
HCT/CV HCT/TP
VP-16 1.19 ± 0.230 16.25 ± 5.373 13.7
Doxorubicin 0.49 ± 0.028 1.69 ± 0.776 3.4
Cisplatin 8.56 ± 0.930 18.10 ± 1.220 2.1
Cell survival was determined with the MTT assay. The relative resis-
tance of the cells was determined by division of the IC50 value of TP-
transfected cell lines (HCT/TP) for each agent divided by the IC50
value of mock-transfected cell lines (HCT/CV) for the same agent.
Values are the means ± S.D. of three experiments.
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contrast negligible induction of luciferase activity was ob-
served following VP-16 treatment and only a 2.2-fold enhance-
ment was observed following UV treatment of p53-null cells.
Treatment of mt-p53-transfected cells with VP-16 or UV in-
duced an enhancement of luciferase activity that was compara-
ble to that of the mock-transfected cells being 2.4 and 2.8-fold,
respectively. These data indicated that DNA damage-inducing
signals could potentiate the transcriptional activity of TP at
least in part through the regulation of p53, although p53-inde-
pendent pathways also exist.
3.4. TP inhibits apoptosis induced by cytotoxic agents
To further analyze the role of TP in the DNA-damage pro-
cess we investigated whether the increased expression of TP
might confer cellular resistance to DNA damage-inducing
agents. We established three TP-overexpressing cell lines,
KB/TP, Jurkat/TP and HCT/TP, that show high expression
of TP compared to mock-transfected cell lines, KB/CV, Jur-
kat/CV and HCT/CV, respectively (Fig. 3).
We used these cells to examine the eﬀect of TP on cellular
susceptibility to DNA damage. Cell viability following VP-
16, doxorubicin, and cisplatin treatment was analyzed with
the MTT assay (Tables 1 and 2). TP-transfected KB/TP and
HCT/TP cells showed signiﬁcant resistance to VP-16, doxoru-
bicin and cisplatin treatment compared to their mock-transfec-
ted counterparts. The sensitivity to staurosporine of KB/TPKB Jurkat HCT-15
TP 50kDa
α- tubulin
CV CVCVTP TP TP
Fig. 3. TP-overexpressing cell lines. Immunoblot of TP in KB, Jurkat
and HCT-15 cells transfected with TP cDNA. Cytosolic fractions
(50 lg of protein) were separated by SDS–9.4% PAGE. TP levels were
determined using an anti-TP monoclonal antibody.cells was comparable to that of KB/CV cells. We then exam-
ined whether Jurkat, KB and HCT cells transfected with TP
cDNA are resistant to DNA damage-induced apoptosis.
Apoptotic cells were measured by the proportion of the sub-
G1 fraction. Increased proportions of the sub-G1 fraction were
detected in both TP- and mock-transfected cell lines after
treatment with 100 J/m2 UV, 2–5 lM VP16, 4 lM doxorubicin
and 2.1–50 lM cisplatin. However, the TP-transfected cell
lines showed signiﬁcantly lower susceptibility to DNA damage
than the respective mock-transfectant (Fig. 4A–C).
In contrast, there were no signiﬁcant diﬀerences in sensitivity
to staurosporine or vincristine between TP- and mock-trans-
fected cell lines. These ﬁndings indicated that TP might sup-
press DNA damage-induced apoptosis thereby conferring
resistance to apoptosis on cancer cells.
3.5. The cytoprotective function of TP against DNA damage is
independent of its enzymatic activity
We next examined whether the enzymatic activity of TP is
required for its cytoprotective function. We determined if inhi-
bition of the TP activity with TPI, a speciﬁc TP inhibitor
(Ki = 2 · 108 M), could abrogate its cytoprotective eﬀect
against DNA damage-induced apoptosis. We ﬁrst assayed
the level of TP enzymatic activity in cellular homogenates of
TP-transfected and control cells using a radiometric assay.
Pre-treatment with 200 lM TPI for 12 h dramatically reduced
the TP enzymatic activity in the KB/TP cells to the level lower
than that in the mock-transfected cell line (Fig. 5A). TPI was
not cytotoxic to the cells as it did not have any eﬀect on the
number of apoptotic cells at this concentration (data not
shown). Pre-treatment with TPI did not alter the sub-G1 frac-
tion following the induction of DNA-damage by VP-16, UV,
or VCR in either KB/CV or KB/TP cells (Fig. 5B). TPI treat-
ment was also unable to abrogate the anti-apoptotic eﬀect of
TP in Jurkat cells or HCT cells (data not shown). The fact that
the eﬀect of TP on cellular resistance to DNA damage is unre-
lated to its enzymatic activity was also conﬁrmed by MTT as-
say (Table 2). To conﬁrm the ﬁnding that TP activity is not
required for the cytoprotective eﬀect, we used the KB/TPmt
(L148R) cells that expressed catalytically inactive TP. The
expression level of TP in KB/TP-mt (L148R) cells was similar
to that in KB/TP cells but KB/TP-mt (L148R) cells had no TP
activity [15]. The proportion of the sub-G1 fraction of KB/CV
cells after treatment with 100 J/m2 UV, 2 lM VP-16, 4 lM
Doxorubicin, 2.1 lM cisplatin was higher than that of KB/
TP and KB/TP-mt (L148R) cells, and the proportion of the
sub-G1 fraction of KB/TP-mt (L148R) cells was comparable
to that of KB/TP cells (Fig. 5C).
Table 2
Eﬀects of TP and TP activity on the cytotoxicity of DNA-damaging agents
IC50 (lM) Fold resistance IC50 (lM) Fold resistance
KB/CV KB/TP KB/CV + TPI KB/TP + TPI
VP-16 2.45 ± 0.144 15.72 ± 4.859 6.41 2.20 ± 0.151 13.65 ± 1.229 6.20
Doxorubicin 0.25 ± 0.008 0.873 ± 0.098 3.44 0.27 ± 0.008 0.778 ± 0.10 2.96
Staurosporine 58.8 ± 4.13 56.99 ± 6.153 0.97 47.9 ± 8.440 77.37 ± 3.84 1.68
Cell survival with or without 200 lM of TPI was determined with the MTT assay. The relative resistance of the cells was determined by division of
the IC50 value of TP-transfected cell lines (KB/TP) for each agent divided by the IC50 value of mock-transfected cell lines (KB/CV) for the same
agent. Values are the means ± S.D. of three experiments.
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Fig. 4. The eﬀects of DNA damage-inducing agents on the apoptotic fraction of TP-transfected cell lines. Apoptotic cells were estimated by
determination of the proportion of cells in the sub-G1 fraction. Flow cytometry of propidium iodide-stained cells was performed in the presence of
the indicated doses of DNA damage-inducing agents. (A) Jurkat/CV (open bar) and Jurkat/TP (closed bar), (B) KB/CV (open bar) and KB/TP
(closed bar) and (C) HCT/CV and HCT/TP cells. Each column and bar represents the means ± S.D. of three independent experiments.
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Fig. 5. The cytoprotective function of TP is independent of its enzymatic activity. (A) KB/CV cells and KB/TP cells were seeded 1 · 106 cells/well in
12 well plates and cultured with or without 200 lM of TPI under normoxic condition for 24 h. Enzymatic activities were determined by adding [14C]
thymidine in the culture media and measuring the conversion to [14C] thymine. (B) Cells were pre-treated with TPI (500 lM) for 12 h before the
addition of DNA damage-inducing stimuli. Eﬀects of TPI on the apoptotic proportions of KB/CV (open bar) and KB/TP (closed bar). (C) KB/CV
cells, KB/TP cells and KB/TP-mt (L148R) were exposed to the DNA-damage-inducing stimuli UV (100 J/m2), cisplatin (2.1 lM), VP-16 (2 lM),
doxorubicin (4 lM), VCR (0.007 lM) over 48 h. Apoptotic cells were estimated by the proportion of the sub-G1 fraction. Flow cytometry of
propidium iodide-stained cells was performed in the presence of indicated doses of DNA damaging agents.
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augmented in TP-overexpressing cell line
We next investigated if TP could exert its protective eﬀect by
modulation of the cell cycle. We investigated the eﬀect of TP
on the proportion of cells in the major stages of the cell cycle.
Jurkat/CV and Jurkat/TP cells were UV irradiated (80 J/m2)
and the percentage of cells in the stages of the cell cycle was
measured over 24 h. The Jurkat/TP cells showed a higher frac-
tion of cells in the G1 stage than control cells in the absence of
treatment (Fig. 6). Following exposure to UV, Jurkat/TP cells
maintained a higher G1 fraction of cells at both 12 and 24 h
than Jurkat/CV cells. The G1 fractions of Jurkat/CV and Jur-
kat/TP cells were, respectively: 52% and 58% at 6 h, 40% and
58% at 12 h, and 30% and 46% at 24 h.
3.7. Akt activation was augmented in TP-transfected cell lines
We next determined if the anti-apoptotic eﬀect of TP might
be mediated by Akt activation. KB/CV and KB/TP cells wereexposed to UV at 80 J/m2 and the activation of Akt was exam-
ined by Western blot using the anti-phosphorylated Akt anti-
body. A low basal level of Akt phosphorylation was
detectable in both cell lines and this was enhanced as early
as 30 min following UV exposure (Fig. 7A). In KB/CV cells
Akt phosphorylation was maintained for up to 2 h, after which
the phosphorylated Akt gradually declined and had returned
to the basal level by 10 h. In contrast, the phosphorylated
Akt in KB/TP was maintained at high levels for up to 10 h.
The total amount of Akt was also higher in the KB/TP cells
than in the KB/CV cells. We also had similar data with
HCT/CV and HCT/TP cells (Fig. 7B). Similar patterns of
Akt phosphorylation and protein expression were observed
in the HCT-15 cells following UV exposure, and in the Jurkat
cells following cisplatin treatment (data not shown). These
data suggest that Akt activity tends to be augmented in TP-
transfected cell lines, especially in the presence of DNA dam-
age-inducing stimuli.
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dependent on the PI3K/Akt pathway
To further analyze the role of the Akt pathway in TP-in-
duced cytoprotection we determined the eﬀect of inhibition
of PI3K on the percentage of apoptotic cells. PI3K activity
is essential for the phosphorylation of Akt. HCT and KB cells
were pre-treated with the PI3K inhibitors, LY294002 and
wortmannin for 1 h prior to induction of DNA damage with
either UV (HCT cells) or VP-16 (KB cells) (Fig. 8A and B).
As expected, the addition of 25 lM LY294002 or 500 nM
wortmannin abrogated the expression of phosphorylated Akt
almost completely in both cell lines. Moreover, LY294002did not aﬀect on the expression of either the phosphorylated
ERK or the total level of ERK (Fig. 8B).
LY294002 or wortmannin treatment signiﬁcantly attenuated
the protective eﬀect of TP on apoptosis in the TP-overexpress-
ing cell lines, HCT/TP and KB/TP (Fig. 8C and D). These re-
sults indicate that PI3K activation might be required for the
TP-associated cytoprotection against DNA-damaging agents.4. Discussion
Previous studies demonstrated that TP is expressed at higher
levels in a wide variety of tumors than in the adjacent non-neo-
plastic tissues. Considering the critical role that TP plays in tu-
mor progression and angiogenesis, it is important to
understand the cellular mechanisms by which TP expression
is modulated and the molecular mechanisms by which TP ex-
erts its eﬀects in vivo.
TP expression has been previously shown to be upregulated
by various inﬂammatory cytokines of monocyte/macrophage
origin such as IL-1a, TNF-a and IFN-c. This inﬂammation-
mediated upregulation of TP might provide favorable condi-
tions for angiogenesis and malignancy of human tumors
[13,19]. However the biological role of tumor cell-derived TP
is not yet clariﬁed. We found in this study that many stimuli
other than cytokines, such as hypoxia, hyperosmotic shock,
acidosis and mitogen starvation, could enhance TP transcrip-
tional activity and protein expression. These eﬀects are consis-
tent with other studies on the regulation of TP expression.
Oxygen tension and pH have been shown to modulate TP
expression in human breast tumor cells in vitro and in vivo
[20].
In this study, TP promoter activity was also enhanced by
thymidine, but not by thymine. This eﬀect of thymidine and
thymine on the transcriptional activity of the TP promoter
mirrors previous data in which TP enzymatic activity was en-
hanced by thymidine and inhibited by thymine [21] and sug-
gests a catabolic role for TP.
Of particular importance to cancer chemotherapy, we found
that TP expression was inﬂuenced by DNA damage-inducing
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doxorubicin and UV enhanced not only TP transcriptional
activity but also its protein expression.
We have also addressed the possible molecular mechanisms
by which TP induces protection against DNA damage-induc-
ing agents. P53 plays an important role in mediating the re-
sponse to stress induced by DNA damage that results in
apoptosis [22] and the apoptosis inducing activity of p53 is a
major contributor to its tumor suppressor function. It there-
fore seemed likely that p53 might play a role in modulating
the TP promoter during DNA damage induced by stress.
Our data do suggest some role for p53 in enhancement of
TP promoter activity and this eﬀect was enhanced following
the induction of DNA damage-induced stress. Although the
biological signiﬁcance of the promotion of TP transcription
by p53 is not clear at the present time, a strong association
of TP and p53 in DNA damage and apoptotic process war-
rants further investigation. However, while this study indicates
that DNA damage-inducing agents can potentiate TP pro-
moter activity through a pathway that involves p53, it also
indicates that there exist p53-independent pathways by which
this can be achieved. Thus, transfection of mutated p53 could
not potentiate TP promoter activity yet treatment with DNA
damaging agents enhanced TP promoter activity in p53 mu-tant cells to a level that was comparable to that in the cells that
do not express p53. Furthermore, TP could induce protection
against apoptosis induced by DNA damage-inducing agents in
all the cell lines studied irrespective of their p53 status includ-
ing Jurkat cells (p53-null), KB cells (p53-wt) and HCT-15
(p53-mutated).
We have previously reported that cytoprotection of TP-over-
expressing cell lines against Fas-induced apoptosis might be
mediated by TP-induced suppression of the release of cyto-
chrome c from the mitochondria and subsequent activation
of caspase-3 and -9 [8]. TP-transfected Jurkat/TP showed a sig-
niﬁcant resistance to VP-16, Adriamycin and cisplatin treat-
ment compared to their mock-transfected counterparts [9].
We also investigated the role of the TP enzymatic activity in
modulation of the TP-protective eﬀect against DNA damage-
inducing agents. TP enzymatic activity has been shown to be
important for TP-induced resistance to hypoxia-induced apop-
tosis in cancer cells, and the TP eﬀect was inhibited by 2-
deoxy-L-ribose, a stereoisomer of 2-deoxy-D-ribose. However
recent reports suggest that the enzymatic activity of TP may
not be required for the TP-induced cytoprotection against
apoptosis induced by cisplatin and Fas. Inhibition of TP
enzymatic activity with a speciﬁc inhibitor of TP could not
inhibit TP-dependent suppression of Fas-induced apoptosis in
1302 H.-C. Jeung et al. / FEBS Letters 580 (2006) 1294–1302TP-transfectedKB cells [8]. Jurkat/TPMu (L148R) cells that had
no TP activity also showed comparable cytoprotective activity
against VP-16, cisplatin and Adriamicin to Jurkat/TP cells [9].
In this study, we found that TP-mediated resistance to apop-
tosis induced by DNA damage-inducing agents was indepen-
dent of the enzymatic activity of TP. This ﬁnding conﬁrms
and expands the previous results. Further study is needed to
elucidate its eﬀects independent of its enzymatic activity.
Since Akt plays an important role in cell survival, we exam-
ined the role of activation of Akt in the apoptotic process in-
duced by DNA damage and its potential modulation by TP.
Both Akt activity (phosphorylated Akt) and Akt protein were
higher in TP-transfected cell lines than in the mock-transfec-
tants, and the Akt activity was signiﬁcantly abrogated by
PI3K inhibitors. Our data suggest that the PI3K/Akt pathway
might be implicated in the cytoprotective activity of TP against
apoptosis induced by DNA damage-inducing agents. Further
study is needed to elucidate whether PI3K/Akt pathway really
plays an important role in the TP-induced protection against
DNA damage, and to clarify the targets of TP in the PI3K/
Akt pathway.
The data presented here demonstrated that expression of TP
is increased in response to various stimuli including DNA
damage, and that TP molecules, but not the enzymatic activity
of TP confer resistance to DNA damage-induced apoptosis in
cancer cells.
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